Nuvation Bio Inc. is trading 13.3% up at $5.44, rebounding sharply from last week’s pullback as momentum continues following a major analyst upgrade.
- RBC Capital recently raised its price target on the stock to $20 from $13, maintaining an Outperform rating based on optimism surrounding the company's brain cancer program.
- The call is noted as one of the most aggressive small-cap biotech moves this year, providing significant upside support as broader markets trade higher.